NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	57.84M 0 19.09M 16.45M 15.57M 14.11M 26.48M 1.82B 26.61M 185M 71.12M 928M 71.68M 70.11M 2.93B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	57.84M 0 19.09M 16.45M 15.57M 14.11M 26.48M 1.82B 26.61M 185M 71.12M 928M 71.68M 70.11M 2.93B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	31.94%	Yield 2026 *	-	Yield 2027 *	-

07-31	NewcelX Ltd. announced that it expects to receive $1.399991 million in funding	CI
07-15	NewcelX Obtains Patent in Brazil for Potential Type 1 Diabetes Treatment	MT
07-09	Newcelx Ltd. Announces Appointment of Camillo Ricordi to Scientific Advisory Board	CI
07-07	NewcelX Ltd. announced that it has received $2.940234 million in funding	CI
07-01	NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes	CI
06-15	NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology Platform	CI
05-27	Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes	RE
05-27	NewcelX Submits Pre-IND Package To FDA For NCEL-101 For The Treatment Of Type 1 Diabetes	CI
05-01	NewcelX Ltd. announced that it has received $1.349994 million in funding	CI
04-30	NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-29	NewcelX Ltd. Auditor Raises 'Going Concern' Doubt	CI
04-20	Newcelx updates corporate presentation to highlight type 1 diabetes flagship program	RE
04-02	NewcelX Ltd. announced that it expects to receive $1.349994 million in funding	CI

07-31	NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing	AQ
07-15	NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio	AQ
07-08	NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board	AQ
07-08	The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy	AQ
07-01	NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KADIMASTEM	-.--%	-8.93%	-	-	19.09M
LONZA GROUP AG	-0.71%	-6.35%	-4.87%	+9.03%	45.48B
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+340.68%	+519.93%	43.69B
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+37.28%	+21.57%	43.09B
BEONE MEDICINES AG	+1.38%	-3.28%	+3.23%	+65.60%	39.4B
CELLTRION, INC.	-1.44%	-5.26%	+8.78%	+36.85%	31.91B
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+18.07%	+110.32%	16.4B
EUROFINS SCIENTIFIC SE	-0.31%	-2.78%	+10.47%	+30.49%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+74.20%	+39.37%	13.28B
Average	+0.44%	-3.57%	+60.98%	+104.14%	29.42B
Weighted average by Cap.	+0.41%	-3.67%	+73.16%	+123.57%

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-

Kadimastem Stock TEL AVIV STOCK EXCHANGE

Stocks

KDST

IL0011284614

Biotechnology & Medical Research

Valuation : Kadimastem

Chart: Kadimastem

Latest news : Kadimastem

Analysts' recommendations : Kadimastem

Press Releases : Kadimastem

Other Biotechnology & Medical Research

Financials

Company Profile